Pharmalucence formally CIS-US Inc.
Careers News Resources Contact  
    Company
 
  Manufacturing Capabilities
 
  Facility Details 
 
  Nuclear Medicine Products
 
 
 





Company News
Come See Us
Pharmalucence
Company News



September 17, 2012

FDA grants Orphan Drug designation status to Sulfur Colloid.

Pharmalucence receives FDA notification that Sulfur Colloid Injection (SCI) has been granted Orphan Drug designation status and seven years of market exclusivity for its use in lymph node localization in melanoma patients.

PDF





For more information, please contact:
John Felock
Director; Sales, Marketing and Customer Service
1-781-687-1245
jfelock@pharmalucence.com



29 Dunham Road, Billerica, MA 01821 | Telephone: 781-275-7120    © Pharmalucence Inc. All rights reserved.
HOME   |   SITE MAP   |   LEGAL STATEMENT   |   PRIVACY POLICY   |